ENDRA Life Sciences (NDRA) Operating Expenses (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Operating Expenses for 11 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 47.95% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $6.5 million (down 31.96% YoY), while the FY2025 annual figure was $5.8 million, down 46.72% from the prior year.
• Operating Expenses improved to $2.2 million in Q1 2026 per NDRA's latest filing, from $1.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $4.3 million in Q4 2024 and bottomed at $1.3 million in Q2 2025.
• Historically, Operating Expenses has averaged $2.5 million across 5 years, with a median of $2.8 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Expenses jumped 194.75% — and 2025, when it plunged 62.25%.
• ENDRA Life Sciences' Operating Expenses stood at $3.3 million in 2022, then sank by 56.0% to $1.5 million in 2023, then surged by 194.75% to $4.3 million in 2024, then slumped by 62.25% to $1.6 million in 2025, then soared by 34.01% to $2.2 million in 2026.
• Business Quant data shows NDRA's Operating Expenses at $2.2 million in Q1 2026, $1.6 million in Q4 2025, and $1.4 million in Q3 2025.